# Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy

> **NCT04037462** · PHASE1,PHASE2 · TERMINATED · sponsor: **VA Office of Research and Development** · enrollment: 2 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Immunotherapy

## Interventions

- **DRUG:** Dexamthasone

## Key facts

- **NCT ID:** NCT04037462
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-07
- **Primary completion:** 2022-02-23
- **Final completion:** 2023-02-23
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2024-06-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04037462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04037462, "Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04037462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*